Propionylpromazine hydrochloride

CAS No. 7681-67-6

Propionylpromazine hydrochloride( Propiopromazine hydrochloride )

Catalog No. M24770 CAS No. 7681-67-6

Propionylpromazine hydrochloride is a dopamine receptor D2 (DRD2) antagonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 67 In Stock
10MG 110 In Stock
25MG 177 In Stock
50MG 266 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Propionylpromazine hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Propionylpromazine hydrochloride is a dopamine receptor D2 (DRD2) antagonist.
  • Description
    Propionylpromazine hydrochloride is a dopamine receptor D2 (DRD2) antagonist.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Propiopromazine hydrochloride
  • Pathway
    GPCR/G Protein
  • Target
    Dopamine Receptor
  • Recptor
    D2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    7681-67-6
  • Formula Weight
    376.94
  • Molecular Formula
    C20H25ClN2OS
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:80mg/ml(212.24mM; need ultrasonic); H2O:8mg/ml(21.22mM; need ultrasonic)
  • SMILES
    CCC(C(C=C1N2CCCN(C)C)=CC=C1SC3=C2C=CC=C3)=O.[H]Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Tyers M , Diamandis P , Dirks P B . Method for treating a brain cancer with ifenprodil[J]. US, 2011.
molnova catalog
related products
  • Seridopidine

    Seridopidine (ACR343) is a modulator of dopaminergic activity that is used as an oral therapy for schizophrenia, Parkinson's disease, and Tourette's syndrome.

  • ACEPROMAZINE MALEATE

    ACEPROMAZINE MALEATE is a dopamine receptor antagonist.

  • Dexpramipexole dihyd...

    A partial/full agonist of dopamine receptor with Ki of 3.9/2.2/0.5/5.1 nM for D2S/D2L/D3/D4, respeectively.